 |
| |
| Apr-29-19 | Upgrade |
BMO Capital Markets |
Underperform → Market Perform |
|
|
| Mar-25-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| Jan-23-19 | Initiated |
UBS |
Neutral |
$91 |
|
| Jan-03-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Dec-26-18 | Initiated |
Standpoint Research |
Buy |
|
|
| Oct-22-18 | Reiterated |
SunTrust |
Buy |
$157 → $135 |
|
| Oct-04-18 | Reiterated |
BofA/Merrill |
Buy |
$107 → $106 |
|
| Jun-01-18 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| May-30-18 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Jan-30-18 | Reiterated |
Morgan Stanley |
Equal-Weight |
$99 → $131 |
|
| Jan-29-18 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Oct-30-17 | Reiterated |
Leerink Partners |
Outperform |
$108 → $107 |
|
| Oct-02-17 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Sep-25-17 | Downgrade |
UBS |
Buy → Neutral |
$79 → $92 |
|
| Aug-17-17 | Initiated |
Evercore ISI |
Outperform |
$95 |
|
| Jun-22-17 | Upgrade |
Societe Generale |
Hold → Buy |
|
|
| Mar-22-17 | Upgrade |
Societe Generale |
Sell → Hold |
|
|
| Oct-31-16 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| Oct-18-16 | Initiated |
Leerink Partners |
Mkt Perform |
$70 |
|
| Sep-08-16 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
|
|
| May-22-19 09:50AM | Lilly's Crohn's Disease Candidate Meets Phase II Study Goals Zacks |
| 09:23AM | 3 Top Dividend Stocks With Yields Over 5% Motley Fool |
| 08:47AM | Top Ranked Income Stocks to Buy for May 22nd Zacks |
| 07:19AM | Go Beyond Bargains: Play 5 Stocks With Rising P/E Instead Zacks |
| May-21-19 03:58PM | Top Marijuana Stocks That Pay Dividends Investopedia |
| 09:00AM | Better Buy: AbbVie vs. Pfizer Motley Fool |
| 08:00AM | AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group |
| 07:47AM | Top Ranked Income Stocks to Buy for May 21st Zacks |
| 07:15AM | 3 Top Dividend Stocks to Buy Right Now Motley Fool |
| May-20-19 12:31PM | Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch |
| 09:02AM | AbbVie's Brain Cancer Candidate Fails in Phase III Study Zacks |
| May-19-19 07:00AM | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big Motley Fool |
| May-17-19 05:19PM | Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL Zacks |
| 09:19AM | AbbVie halts enrollment after brain cancer trial misses goal, shares fall Reuters |
| 09:00AM | AbbVie halts patient enrollment after brain cancer trial misses goal Reuters |
| 09:00AM | AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial MarketWatch |
| 08:45AM | AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer PR Newswire |
| 08:35AM | Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs Zacks |
| May-15-19 02:19PM | AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients PR Newswire |
| 09:15AM | Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks |
| 08:45AM | 3 Reasons Why AbbVie (ABBV) Is a Great Growth Stock Zacks |
| 07:46AM | AbbVie Settles Humira Litigation With Boehringer Ingelheim Zacks |
| 12:57AM | PRESS DIGEST -Wall Street Journal - May 15 Reuters |
| May-14-19 10:43AM | AbbVie Rises 3% Investing.com |
| 10:13AM | MC10, Inc. and AbbVie (NYSE:ABBV) Announce Clinical Trials in Multiple Sclerosis Using the BioStamp nPoint® System Business Wire |
| 10:07AM | Here are the stocks to buy if an all-out U.S.-China trade war erupts, says Goldman MarketWatch |
| 08:57AM | AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S. MarketWatch |
| 08:34AM | AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim PR Newswire |
| 08:00AM | AbbVie to Present at the UBS Global Healthcare Conference PR Newswire |
| May-13-19 06:00AM | AbbVie- Unique Mix of Growth, Yield and Value MoneyShow |
| May-09-19 01:39PM | Parnassus Endeavor Fund Buys 2 Pharmaceutical Stocks in 1st Quarter GuruFocus.com |
| May-08-19 04:49PM | Parnassus Endeavor Fund Buys AbbVie, Boosts Biogen GuruFocus.com |
| 07:47AM | Top Ranked Income Stocks to Buy for May 8th Zacks |
| May-07-19 08:00AM | AbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference PR Newswire |
| May-06-19 09:21AM | The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo Zacks |
| 09:11AM | Top Ranked Income Stocks to Buy for May 6th Zacks |
| 06:37AM | Two Healthcare Stocks in the XLV Fund Stand Out InvestorPlace |
| 06:30AM | Alector Announces First Alzheimers Disease Patient Dosed in Phase 1b Study of AL002 GlobeNewswire |
| May-03-19 11:37AM | Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates Zacks |
| 06:10AM | Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod Zacks |
| May-02-19 01:21PM | These 6 biotech stocks are promising takeover targets MarketWatch |
| May-01-19 06:56PM | The Top Pharma Stocks for 2019 Investopedia |
| 01:55PM | Profit from Earnings Volatility With This Biotech Stocks Pairs Trade InvestorPlace |
| 08:55AM | The Zacks Analyst Blog Highlights: Facebook, Comcast, AbbVie, Union Pacific and Air Products Zacks |
| Apr-30-19 02:52PM | Top Stock Reports for Facebook, Comcast & AbbVie Zacks |
| 07:45AM | European Commission Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis PR Newswire |
| 07:08AM | AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting PR Newswire |
| Apr-29-19 05:08PM | Better Big Pharma Stock: AbbVie vs. AstraZeneca Motley Fool |
| 09:15AM | Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks |
| 09:00AM | AbbVie (ABBV) Upgraded to Buy: Here's Why Zacks |
| 08:45AM | 3 Reasons Why Growth Investors Shouldn't Overlook AbbVie (ABBV) Zacks |
| 07:59AM | Here are the biggest analyst calls of the day: Target, Disney, CVS, American Airlines, & more CNBC |
| Apr-28-19 09:00AM | Better Buy: Pfizer vs. AbbVie Motley Fool |
| Apr-27-19 01:00PM | Why AbbVie Is in Better Shape Than You Might Think Motley Fool |
| 11:44AM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga |
| 11:29AM | Biosimilar competition to AbbVies Humira is eroding profits, but company says it has confidence in pipeline MarketWatch |
| Apr-26-19 06:37PM | Edited Transcript of ABBV earnings conference call or presentation 25-Apr-19 1:00pm GMT Thomson Reuters StreetEvents |
| 05:36PM | 2 Large Drug Manufacturers Release 1st-Quarter Results GuruFocus.com |
| 04:26PM | Gut Check: The Bacteria In Your Intestines Could Help Cure Cancer Investor's Business Daily |
| 08:00AM | 3 Big Stock Charts for Friday: AbbVie, ConocoPhillips and MGM Resorts InvestorPlace |
| Apr-25-19 05:03PM | AbbVie Inc (ABBV) Q1 2019 Earnings Call Transcript Motley Fool |
| 04:06PM | These Pharmas Beat First-Quarter Forecasts; But Biosimilars Rankled One Investor's Business Daily |
| 03:57PM | AbbVie Climbs Earnings Beat, Guidance Boost TheStreet.com |
| 02:00PM | What You Need to Know About AbbVie's Surprisingly Strong Q1 Earnings Motley Fool |
| 11:56AM | AbbVie raises profit forecast, but Humira concerns weigh on shares Reuters |
| 11:15AM | AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View Zacks |
| 11:13AM | AbbVie Is Losing Its Humira Safety Blanket Bloomberg |
| 10:04AM | AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters |
| 08:50AM | AbbVie (ABBV) Beats Q1 Earnings and Revenues, Shares Up Zacks |
| 08:34AM | AbbVie raises forecasts despite pressure on Humira Financial Times |
| 08:08AM | AbbVie stock up 2% after earnings beat and raised outlook MarketWatch |
| 07:58AM | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga |
| 07:52AM | AbbVie: 1Q Earnings Snapshot Associated Press |
| 07:42AM | AbbVie Reports First-Quarter 2019 Financial Results PR Newswire |
| 03:47AM | AbbVie Earnings, Revenue Beat in Q1 Investing.com |
| Apr-24-19 04:29PM | Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? Zacks |
| 04:25PM | Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks |
| 04:13PM | AbbVie Expected to Earn $2.06 a share TheStreet.com |
| 01:50PM | AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Heres what to expect MarketWatch |
| 01:44PM | 5 Turnaround Earnings Charts You Must See Zacks |
| 11:40AM | Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales Zacks |
| 11:31AM | Why Earnings Season Could Be Great for AbbVie (ABBV) Zacks |
| 10:24AM | You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch |
| 08:09AM | The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga |
| Apr-23-19 07:31PM | AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval Reuters |
| 06:37PM | AbbVie stock ticks higher on FDA approval of psoriasis treatment MarketWatch |
| 06:19PM | AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis PR Newswire |
| Apr-22-19 05:00PM | Better Buy: Biogen vs. AbbVie Motley Fool |
| 10:33AM | Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks |
| 10:17AM | Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks |
| 08:15AM | AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect Motley Fool |
| Apr-20-19 08:00AM | 3 Cancer Treatment Stocks to Buy in April Motley Fool |
| Apr-19-19 02:12PM | 5 Top Pharmaceutical Stocks to Buy in 2019 Motley Fool |
| 12:19PM | 5 Top Biotech Stocks to Buy in 2019 Motley Fool |
| Apr-18-19 10:59AM | Can Q1 Earnings Lift Healthcare ETFs Higher? Zacks |
| 10:33AM | AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? Zacks |
| 10:22AM | Here Are the Key Takeaways From J&J's Q1 Earnings Report Zacks |
| 10:04AM | Health Canada Approves SKYRIZI (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis CNW Group |
| Apr-17-19 09:30AM | AbbVie Falls 3% Investing.com |
| Apr-16-19 09:28PM | Is TG Therapeutics a Buy? Motley Fool |
|
|
|
|
| AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Durkin Brian L | VP, Controller | Mar 25 | Sale | 79.69 | 475 | 37,853 | 9,121 | Mar 25 04:34 PM | | Schumacher Laura J | Vice Chairman | Mar 14 | Sale | 80.00 | 25,000 | 2,000,000 | 139,838 | Mar 15 05:53 PM | | SALEKI-GERHARDT AZITA | EVP, Operations | Mar 05 | Sale | 79.03 | 15,797 | 1,248,480 | 93,312 | Mar 06 05:03 PM | | Schumacher Laura J | Vice Chairman | Dec 28 | Sale | 90.00 | 25,000 | 2,250,000 | 134,322 | Jan 02 04:49 PM | | CHASE WILLIAM J | EVP, Finance & Administration | Dec 12 | Sale | 90.00 | 60,000 | 5,400,000 | 104,863 | Dec 14 05:12 PM | | GONZALEZ RICHARD A | Chairman of the Board and CEO | Dec 11 | Sale | 88.75 | 16,850 | 1,495,438 | 286,203 | Dec 13 04:56 PM | | Schumacher Laura J | Executive Vice President | Dec 04 | Option Exercise | 51.42 | 94,140 | 4,840,679 | 192,398 | Dec 07 05:15 PM | | Schumacher Laura J | Executive Vice President | Dec 04 | Sale | 93.58 | 94,140 | 8,809,552 | 98,258 | Dec 07 05:15 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Nov 29 | Sale | 90.10 | 42,450 | 3,824,940 | 30,350 | Nov 30 05:22 PM | | SEVERINO MICHAEL | EVP, R&D and CSO | Aug 17 | Sale | 97.52 | 50,000 | 4,876,060 | 82,281 | Aug 21 04:58 PM | | TILTON GLENN F | Director | Jun 27 | Buy | 91.90 | 5,400 | 496,274 | 39,735 | Jun 29 02:30 PM | | RAPP EDWARD J | Director | Jun 20 | Buy | 98.63 | 1,013 | 99,909 | 20,743 | Jun 22 05:56 PM |
|
|
|
|
|
|
